Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Stock Information for G1 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About G1 Therapeutics Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.